ATI-9494 / Aclaris - LARVOL DELTA

Fourth Quarter 2025 Highlights and Recent Updates (The Manila Times) - "Confirmed Expectation of Top Line Results in the Second Half of 2026 from Ongoing Phase 2 Trial of Investigational Anti-TSLP Monoclonal Antibody Bosakitug: This randomized, double-blind, placebo-controlled Phase 2 trial is designed to evaluate bosakitug in approximately 96 patients with moderate-to-severe AD...Aclaris intends to file an IND for ATI-9494 in the second half of 2026."

IND • P2 data • Atopic Dermatitis • Immunology